lung%20cancer
LUNG CANCER
Lung cancer is having a malignant tumor in the lungs especially in the cells lining air passages.
Primary tumor-related signs and symptoms are cough, dyspnea, hemoptysis, and chest discomfort.
Signs and symptoms due to intrathoracic spread may involve the nerves (hoarseness, dyspnea, muscle wasting of upper limb, Horner's syndrome), chest wall and pleura (chest pain, dyspnea) and vascular structures (facial swelling, dilated neck veins, cardiac tamponade) & viscera (dsyphagia).
The signs and symptoms due to metastatic spread are bone pain with or without pleuritic pain, neurologic symptoms, limb weakness, unsteady gait, cervical lymphadenopathy, and skin nodules.

Follow Up

 Follow-Up After Therapy for Patients with Non-Small Cell Lung Cancer (NSCLC)

  • Studies have shown 6.5% annual recurrence rate of non-small cell lung cancer (NSCLC) stage I & small cell lung cancer (SCLC), respectively
  • Observation for complications of treatment is recommended for at least 3-6 months
  • Follow up with history, physical exam & chest CT scan with or without contrast is advised every 6 months for 2-3 years; then history, physical exam & chest CT scan without contrast annually thereafter for patients with Stage I-II NSCLC given primary treatment including surgery with or without chemotherapy
    • High-resolution CT scan is recommended 4 years after surgical resection of stages IA to IIIA NSCLC, followed by low dose computed tomography (LDCT) every year starting in the 5th year
    • Peak incidence of recurrence is between 2 & 3 years
  • For patients with Stage I-II NSCLC given primary treatment with radiotherapy, & patients diagnosed with Stage III or IV NSCLC, history, PE, & chest CT scan with or without contrast is advised every 3-6 months for 3 years; then history, PE & chest CT scan with or without contrast every 6 months for 2 years, then history & PE with low-dose chest CT scan without contrast annually
  • Biomarkers (eg ALK fusion oncogene, ROS1 gene rearrangements, BRAF V600E mutations, EGFR mutations, PD-1 ligand) may be utilized to predict treatment outcome or disease prognosis
  • Patients who smoke should be advised to quit
    • Please see Smoking Cessation Disease Management Chart for more details
  • Immunizations (pneumococcal vaccine, influenza vaccine, Herpes zoster vaccine) may also be given

Follow-Up After Therapy for Patients with Small Cell Lung Cancer (NSCLC)

  • Patients with limited disease are advised to follow up every 3 months for the 1st year or two, then every 6 months during the 3rd year, then annually after recovery
  • Patients with extensive disease are advised to follow up every 2 months during the 1st year, then every 3-4 months on years 2-3, then every 6 months on years 4-5, then annually
  • Response assessment using chest & abdominal CT scan with contrast depends on previous treatment given & stage of patient's disease:
    • Limited disease small cell lung cancer (LD SCLC) patients given adjuvant chemotherapy or chemoradiotherapy: Only after completion of treatments
    • Limited disease small cell lung cancer (LD SCLC) patients given systemic therapy or chemoradiotherapy: After every 2 cycles of systemic therapy & at completion of treatments
    • Extensive disease small cell lung cancer (ED SCLC) patients given systemic therapy: After every 2-3 cycles of systemic therapy & at completion of therapy
  • Response assessment of extensive disease small cell lung cancer (ED SCLC) patients with asymptomatic brain metastasis receiving systemic therapy prior to whole-brain radiotherapy should undergo brain magnetic resonance imaging (MRI) or computed tomography (CT) scan with contrast every 2 cycles of chemotherapy & after completion of therapy
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
6 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.